Delpazolid Emerges as a Safer Oxazolidinone Alternative for Tuberculosis: Results from the PanACEA-DECODE-01 Trial
Posted inInfectious Diseases news Respiratory

Delpazolid Emerges as a Safer Oxazolidinone Alternative for Tuberculosis: Results from the PanACEA-DECODE-01 Trial

The Phase 2b PanACEA-DECODE-01 trial identifies delpazolid 1200 mg once daily as an effective and safer oxazolidinone alternative to linezolid, demonstrating a 38% faster mycobacterial load decline when added to a bedaquiline, delamanid, and moxifloxacin backbone for pulmonary tuberculosis treatment.
Sutezolid Enhances Bactericidal Activity Without Class-Specific Toxicities: Insights from the PanACEA-SUDOCU-01 Trial
Posted inInfectious Diseases news Respiratory

Sutezolid Enhances Bactericidal Activity Without Class-Specific Toxicities: Insights from the PanACEA-SUDOCU-01 Trial

The Phase 2b PanACEA-SUDOCU-01 trial demonstrates that sutezolid significantly increases the bactericidal activity of a bedaquiline-delamanid-moxifloxacin regimen in pulmonary tuberculosis, notably without the neuropathy or myelosuppression typical of linezolid, offering a promising alternative for drug-resistant TB therapy.
Functional Cure Within Reach: GSK’s Bepirovirsen Meets Primary Endpoints in Pivotal Phase III Chronic Hepatitis B Trials
Posted inGastroenterology Infectious Diseases news

Functional Cure Within Reach: GSK’s Bepirovirsen Meets Primary Endpoints in Pivotal Phase III Chronic Hepatitis B Trials

GSK has announced positive Phase III results for Bepirovirsen, an antisense oligonucleotide that achieves functional cure in chronic hepatitis B patients. By targeting viral RNA and HBsAg, the drug offers a finite treatment path, potentially transforming global hepatology standards and replacing lifelong therapy.
Beyond Child Survival: The Evolving Global Burden of Lower Respiratory Infections and Emerging Pathogens (1990-2023)
Posted inInfectious Diseases news Public Health

Beyond Child Survival: The Evolving Global Burden of Lower Respiratory Infections and Emerging Pathogens (1990-2023)

The GBD 2023 study highlights a 33.4% reduction in pediatric LRI mortality since 2010, yet 2.5 million annual deaths persist. While Streptococcus pneumoniae remains the primary pathogen, newly modeled aetiologies like non-tuberculous mycobacteria now account for 22% of the total LRI mortality burden.
Colchicine for Long COVID: Randomized Trial Finds No Benefit in Functional Recovery or Inflammatory Resolution
Posted inInfectious Diseases Internal Medicine news

Colchicine for Long COVID: Randomized Trial Finds No Benefit in Functional Recovery or Inflammatory Resolution

A multi-center randomized clinical trial published in JAMA Internal Medicine demonstrates that colchicine, despite its potent anti-inflammatory properties, fails to improve 6-minute walk test distances or inflammatory markers in patients suffering from Long COVID, highlighting the complexity of the condition's pathogenesis.
Combined Multiplex PCR and Procalcitonin Strategy Fails to Increase Antibiotic-Free Days in Critically Ill Patients with CAP: Insights from the MULTI-CAP Trial
Posted inCritical Care Infectious Diseases news Respiratory

Combined Multiplex PCR and Procalcitonin Strategy Fails to Increase Antibiotic-Free Days in Critically Ill Patients with CAP: Insights from the MULTI-CAP Trial

The MULTI-CAP trial demonstrated that combining multiplex PCR and procalcitonin did not significantly increase the number of antibiotic-free days by Day 28 in ICU patients with pneumonia, although it did successfully reduce the cumulative duration of antibiotic therapy by three days without increasing adverse events.
Hepatitis C Eradication with Direct-Acting Antivirals: A Paradigm Shift in the Treatment of Indolent B-Cell Lymphomas
Posted inHematology-Oncology Infectious Diseases news

Hepatitis C Eradication with Direct-Acting Antivirals: A Paradigm Shift in the Treatment of Indolent B-Cell Lymphomas

Long-term data from the BArT study and prospective observational trials demonstrate that direct-acting antivirals (DAAs) can achieve 100% viral clearance and durable hematologic responses in HCV-associated indolent lymphomas, potentially replacing chemotherapy as a first-line intervention.
Omadacycline Establishes Noninferiority to Moxifloxacin in Community-Acquired Bacterial Pneumonia: The OPTIC-2 Phase 3b Trial Results
Posted inInfectious Diseases news Respiratory

Omadacycline Establishes Noninferiority to Moxifloxacin in Community-Acquired Bacterial Pneumonia: The OPTIC-2 Phase 3b Trial Results

The OPTIC-2 phase 3b trial confirms that omadacycline is noninferior to moxifloxacin for treating community-acquired bacterial pneumonia (CABP). This once-daily aminomethylcycline offers a robust IV-to-oral monotherapy option with a favorable safety profile, particularly for patients with moderate-to-severe disease (PSI Class III/IV).
Hemodynamic vs. Neurological Phenotypes in Adult Invasive Meningococcal Disease: Insights from the Nationwide RETRO-MENINGO Study
Posted inCritical Care Infectious Diseases news

Hemodynamic vs. Neurological Phenotypes in Adult Invasive Meningococcal Disease: Insights from the Nationwide RETRO-MENINGO Study

The RETRO-MENINGO study of 654 adults reveals that hemodynamic presentations of invasive meningococcal disease carry a five-fold higher mortality risk than neurological forms. Early parenteral antibiotic administration remains the most critical modifiable factor for patient survival.
Sacubitril-Valsartan Shows Biological Activity in Chagasic Heart Failure: Insights from the ANSWER-HF Trial
Posted inCardiology Infectious Diseases news

Sacubitril-Valsartan Shows Biological Activity in Chagasic Heart Failure: Insights from the ANSWER-HF Trial

The ANSWER-HF trial compared sacubitril-valsartan to enalapril in patients with Chagasic heart failure. Although the primary endpoint of LVEF improvement was not met at 6 months, significant reductions in NT-proBNP and a favorable win ratio suggest biological activity and safety in this neglected population.
High-Dose Influenza Vaccination Reduces Hospitalizations and Cardiovascular Events in Older Adults: Insights from the FLUNITY-HD Pooled Analysis
Posted inCardiology Infectious Diseases news Public Health

High-Dose Influenza Vaccination Reduces Hospitalizations and Cardiovascular Events in Older Adults: Insights from the FLUNITY-HD Pooled Analysis

The FLUNITY-HD pooled analysis of over 466,000 older adults demonstrates that high-dose inactivated influenza vaccine (HD-IIV) significantly reduces hospitalizations for influenza, pneumonia, and cardiovascular causes, including a 21.3% reduction in heart failure admissions, compared to standard-dose vaccines.
Long COVID-19 in Pregnancy: Elevated Risk Amidst Mild Omicron Infection in a Boosted Vaccinated Cohort During COVID-19 Endemicity
Posted inClinical Updates Infectious Diseases news OB/GYN & Women's Health

Long COVID-19 in Pregnancy: Elevated Risk Amidst Mild Omicron Infection in a Boosted Vaccinated Cohort During COVID-19 Endemicity

Pregnant women show increased risk of long COVID-19 post-SARS-CoV-2 infection during Omicron predominance despite mild disease, yet incidence remains modest in a highly vaccinated cohort, highlighting vaccination’s protective role amidst emerging endemicity.